Skip to main content

Aptose Biosciences Inc.

corporate_fare Company Profile

Aptose Biosciences Inc.

APTOF·OTC·Life Sciences·CIK 0000882361

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for cancer, primarily in the United States. The company's main clinical-stage product is tuspetinib (HM43239), a once-daily oral kinase inhibitor. Tuspetinib has completed Phase 1/2 clinical trials and targets specific kinases involved in myeloid malignancies, including acute myeloid leukemia and higher-risk myelodysplastic syndromes. Aptose Biosciences Inc. holds license agreements with the National Cancer Institute for the clinical development of tuspetinib and with Hanmi Pharmaceutical Co Ltd. for its research, development, and commercialization. The company, incorporated in 1986, was previously known as Lorus Therapeutics Inc. before changing its name to Aptose Biosciences Inc. in August 2014. Its headquarters are located in Toronto, Canada.

Aptose Biosciences Inc. (OTC:APTOF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for APTOF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-30, rated 10/10. Across its 18 most recent items scored 7 or higher, the top rating is 10/10, with 18 rated 8 or above. Recent SEC coverage for APTOF spans 10-K, 8-K, SC 13E3/A, DEFM14A.

Recent high-impact activity:

  • Aptose Biosciences Acquisition by Hanmi Pharmaceutical Finalized; Delisting Imminent
  • Aptose's AML Drug Shows 86% Remission, 100% in TP53-Mutated Patients in Phase 1/2 Trial
  • Aptose Biosciences: Hanmi Acquisition Delayed, Deepening Cash Crisis
  • Aptose Biosciences Reports $7.63M Q1 Net Loss, No Revenue, Amid Cash Concerns
  • Aptose Biosciences Warns of Insufficient Cash to Fund Operations
Browse all tickers starting with A →

No longer listed

APTOF (Aptose Biosciences Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. Aptose Biosciences Inc was acquired by Hanmi Pharmaceutical. The filings and coverage below remain available as an archive.

feed APTOF - Latest Insights

APTOF
Jun 30, 2026, 7:32 PM EDT
Source: GlobeNewswire
Importance Score:
10
Aptose Biosciences Acquisition by Hanmi Pharmaceutical Finalized; Delisting Imminent
Sentiment: Neutral
View Wiseek Article
APTOF
Jun 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Aptose's AML Drug Shows 86% Remission, 100% in TP53-Mutated Patients in Phase 1/2 Trial
Sentiment: Positive
View Wiseek Article
APTOF
May 29, 2026, 8:04 AM EDT
Source: Reuters
Importance Score:
9
Aptose Biosciences: Hanmi Acquisition Delayed, Deepening Cash Crisis
Sentiment: Negative
View Wiseek Article
APTOF
May 13, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
9
Aptose Biosciences Reports $7.63M Q1 Net Loss, No Revenue, Amid Cash Concerns
Sentiment: Negative
View Wiseek Article
APTOF
May 13, 2026, 5:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Aptose Biosciences Warns of Insufficient Cash to Fund Operations
Sentiment: Negative
View Wiseek Article
APTOF
Mar 31, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Shareholders Approve Hanmi Acquisition Amidst Going Concern Warning
Sentiment: Positive
View Wiseek Article
APTOF
Mar 31, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
9
Aptose Biosciences Secures Final Court Approval for Hanmi Acquisition, Reports Positive Clinical Data
Sentiment: Positive
View Wiseek Article
APTOF
Mar 31, 2026, 4:59 PM EDT
Filing Type: 8-K
Importance Score:
8
Shareholders Approve Hanmi Pharmaceutical Acquisition with Strong Majority
Sentiment: Positive
View Wiseek Article
APTOF
Mar 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Glass Lewis Recommends Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition
Sentiment: Positive
View Wiseek Article
APTOF
Mar 19, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
9
ISS Recommends Aptose Biosciences Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition
Sentiment: Positive
View Wiseek Article
APTOF
Feb 23, 2026, 9:36 PM EST
Filing Type: 8-K
Importance Score:
8
Aptose Biosciences Updates Acquisition Timeline, Secures $11.1M Financing from Acquirer Hanmi
Sentiment: Neutral
View Wiseek Article
APTOF
Feb 23, 2026, 8:26 PM EST
Filing Type: SC 13E3/A
Importance Score:
8
Aptose Biosciences Amends Acquisition Agreement, Extends Go-Private Transaction Deadline
Sentiment: Neutral
View Wiseek Article
APTOF
Feb 23, 2026, 8:14 PM EST
Filing Type: DEFM14A
Importance Score:
8
Aptose Biosciences Files Definitive Proxy for Acquisition by Hanmi Pharmaceutical, Sets Shareholder Vote
Sentiment: Neutral
View Wiseek Article
APTOF
Feb 17, 2026, 6:13 AM EST
Filing Type: SC 13E3/A
Importance Score:
9
Aptose Biosciences Files Second Amendment to Going-Private Transaction Statement for Hanmi Acquisition
Sentiment: Neutral
View Wiseek Article
APTOF
Feb 17, 2026, 6:06 AM EST
Filing Type: PRER14A
Importance Score:
9
Aptose Biosciences Files Definitive Proxy for Hanmi Acquisition, Citing Insolvency Risk if Deal Fails
Sentiment: Neutral
View Wiseek Article
APTOF
Feb 09, 2026, 6:15 AM EST
Filing Type: SC 13E3/A
Importance Score:
9
Aptose Biosciences Amends Going-Private Transaction Details, Outlines Investor Rights for Acquirer
Sentiment: Neutral
View Wiseek Article
APTOF
Jan 14, 2026, 9:26 PM EST
Filing Type: SC 13E3
Importance Score:
10
Aptose Biosciences to Go Private in C$2.41 Per Share Arrangement
Sentiment: Negative
View Wiseek Article
APTOF
Jan 14, 2026, 9:23 PM EST
Filing Type: PRER14A
Importance Score:
9
Aptose Biosciences to be Acquired by Hanmi Pharmaceutical Subsidiary for C$2.41 Per Share, Mitigating Insolvency Risk
Sentiment: Positive
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets